Zebra Technologies Corporation (ZBRA)
NASDAQ: ZBRA · Real-Time Price · USD
341.36
+6.12 (1.83%)
At close: Aug 4, 2025, 4:00 PM
362.25
+20.89 (6.12%)
Pre-market: Aug 5, 2025, 9:16 AM EDT
Silk Road Medical Stock Forecast
Stock Price Forecast
The 8 analysts that cover Silk Road Medical stock have a consensus rating of "Buy" and an average price target of $333.25, which forecasts a -2.38% decrease in the stock price over the next year. The lowest target is $254 and the highest is $425.
Price Target: $333.25 (-2.38%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Silk Road Medical stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 3 | 2 | 2 | 2 | 2 | 1 |
| Hold | 5 | 5 | 5 | 5 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 10 | 10 | 10 | 9 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Hold Maintains $280 → $342 | Hold | Maintains | $280 → $342 | +0.19% | Jul 14, 2025 |
| Baird | Baird | Buy Maintains $320 → $367 | Buy | Maintains | $320 → $367 | +7.51% | Jul 14, 2025 |
| Baird | Baird | Buy Maintains $290 → $320 | Buy | Maintains | $290 → $320 | -6.26% | Jun 4, 2025 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $245 → $280 | Hold | Maintains | $245 → $280 | -17.98% | May 28, 2025 |
| Barclays | Barclays | Hold Maintains $326 → $263 | Hold | Maintains | $326 → $263 | -22.96% | Apr 30, 2025 |
Financial Forecast
Revenue This Year
5.37B
from 4.98B
Increased by 7.73%
Revenue Next Year
5.70B
from 5.37B
Increased by 6.15%
EPS This Year
14.70
from 10.18
Increased by 44.36%
EPS Next Year
16.73
from 14.70
Increased by 13.85%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 5.6B | 6.0B | 6.4B | ||
| Avg | 5.4B | 5.7B | 6.0B | ||
| Low | 5.1B | 5.4B | 5.4B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 12.7% | 11.3% | 12.7% | ||
| Avg | 7.7% | 6.1% | 5.1% | ||
| Low | 2.4% | -0.3% | -6.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 15.75 | 19.00 | 23.15 | ||
| Avg | 14.70 | 16.73 | 18.46 | ||
| Low | 12.01 | 13.65 | 15.51 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 54.7% | 29.3% | 38.4% | ||
| Avg | 44.4% | 13.9% | 10.3% | ||
| Low | 17.9% | -7.1% | -7.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.